Corporate News

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech” or the “Company”) is pleased to announce that the Company has [...]

SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts [...]

SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral [...]

SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has significantly reduced its liabilities through stock conversion and payment of accrued [...]

SAN DIEGO, CA / ACCESSWIRE / July 28, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development [...]

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, [...]

March 3, 2020 San Diego, CA USA. – Nascent Biotech, Inc. (OTCQB: NBIO), today announced its intention to begin research on a possible treatment for patients infected with the Coronavirus. [...]

Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. [...]

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the [...]

This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with [...]